Search

Your search keyword '"Docherty, Kieran F."' showing total 12 results
Start Over Author "Docherty, Kieran F." Journal european heart journal
12 results on '"Docherty, Kieran F."'

1. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

Author

Butt, Jawad H, primary, Kondo, Toru, additional, Yang, Mingming, additional, Jhund, Pardeep S, additional, Docherty, Kieran F, additional, Vaduganathan, Muthiah, additional, Claggett, Brian L, additional, Hernandez, Adrian F, additional, Lam, Carolyn S P, additional, Inzucchi, Silvio E, additional, Martinez, Felipe A, additional, de Boer, Rudolf A, additional, Kosiborod, Mikhail N, additional, Desai, Akshay S, additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Shah, Sanjiv J, additional, Zaozerska, Natalia, additional, Wilderäng, Ulrica, additional, Bengtsson, Olof, additional, Solomon, Scott D, additional, and McMurray, John J V, additional

Published
2023
Full Text
View/download PDF

2. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

Author

Yeoh, Su Ern, primary, Osmanska, Joanna, additional, Petrie, Mark C, additional, Brooksbank, Katriona J M, additional, Clark, Andrew L, additional, Docherty, Kieran F, additional, Foley, Paul W X, additional, Guha, Kaushik, additional, Halliday, Crawford A, additional, Jhund, Pardeep S, additional, Kalra, Paul R, additional, McKinley, Gemma, additional, Lang, Ninian N, additional, Lee, Matthew M Y, additional, McConnachie, Alex, additional, McDermott, James J, additional, Platz, Elke, additional, Sartipy, Peter, additional, Seed, Alison, additional, Stanley, Bethany, additional, Weir, Robin A P, additional, Welsh, Paul, additional, McMurray, John J V, additional, and Campbell, Ross T, additional

Published
2023
Full Text
View/download PDF

5. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

Author

Curtain, James P, primary, Docherty, Kieran F, additional, Jhund, Pardeep S, additional, Petrie, Mark C, additional, Inzucchi, Silvio E, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Bengtsson, Olof, additional, Langkilde, Anna Maria, additional, Sjöstrand, Mikaela, additional, Solomon, Scott D, additional, and McMurray, John J V, additional

Published
2021
Full Text
View/download PDF

6. A welcome 'failure' of gliflozins: blood pressure reduction in heart failure.

Author

Docherty, Kieran F and Jhund, Pardeep S

Subjects
HEART failure, BLOOD pressure, EMPAGLIFLOZIN, DIASTOLIC blood pressure, MEDICAL personnel, SYSTOLIC blood pressure, HYPOTENSION
Abstract

In the EMPULSE trial, there was no change in systolic or diastolic blood pressure at 90 days in the empagliflozin group [change in systolic blood pressure 0.1 mmHg, 95 confidence interval (CI) 2.5 to 2.7 mmHg, change in diastolic blood pressure 0.3 mmHg, 95 CI 1.8 to 1.3 mmHg]. Graph: Graphical Abstract Change in systolic blood pressure in patients with heart failure randomized to empagliflozin (EMPEROR-Reduced and EMPEROR-Preserved) or dapagliflozin (DELIVER and DAPA-HF). In patients with a blood pressure 130 mmHg, there was a fall in blood pressure, while for those with a blood pressure of 110130 mmHg and 110 mmHg, there was a rise in blood pressure.[5] This happened in both the placebo and the empagliflozin groups, suggesting some regression to the mean. [Extracted from the article]

Published
2023
Full Text
View/download PDF

7. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Author

Serenelli, Matteo, primary, Böhm, Michael, additional, Inzucchi, Silvio E, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Solomon, Scott D, additional, DeMets, David L, additional, Bengtsson, Olof, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Anand, Inder S, additional, Chiang, Chern-En, additional, Chopra, Vijay K, additional, de Boer, Rudolf A, additional, Diez, Mirta, additional, Dukát, Andrej, additional, Ge, Junbo, additional, Howlett, Jonathan G, additional, Katova, Tzvetana, additional, Kitakaze, Masafumi, additional, Ljungman, Charlotta E A, additional, Verma, Subodh, additional, Docherty, Kieran F, additional, Jhund, Pardeep S, additional, and McMurray, John J V, additional

Published
2020
Full Text
View/download PDF

9. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Author

Docherty, Kieran F, primary, Jhund, Pardeep S, additional, Inzucchi, Silvio E, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Ponikowski, Piotr, additional, DeMets, David L, additional, Sabatine, Marc S, additional, Bengtsson, Olof, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Desai, Akshay S, additional, Diez, Mirta, additional, Howlett, Jonathan G, additional, Katova, Tzvetana, additional, Ljungman, Charlotta E A, additional, O’Meara, Eileen, additional, Petrie, Mark C, additional, Schou, Morten, additional, Verma, Subodh, additional, Vinh, Pham Nguyen, additional, Solomon, Scott D, additional, and McMurray, John J V, additional

Published
2020
Full Text
View/download PDF

10. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.

Author

McMurray, John J V, Solomon, Scott D, Docherty, Kieran F, and Jhund, Pardeep S

Subjects
DAPAGLIFLOZIN, HEART failure, TYPE 2 diabetes, MINERALOCORTICOID receptors, ANGIOTENSINS
Abstract

The article presents the discussion on Dapagliflozin and prevention of adverse outcomes in Heart Failure trial (DAPA-HF) showing the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin. Topics include SGLT2 inhibitors developing as glucose-lowering treatments for patients with type 2 diabetes; and showing consistent benefit of a mineralocorticoid receptor antagonist (MRA) adding to an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor.

Published
2021
Full Text
View/download PDF

12. How robust are clinical trials in heart failure?

Author

Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Petrie, Mark C., and McMurray, John J. V.

Abstract

Aims Guidelines for the management of chronic heart failure (CHF) cite the results of randomized controlled trials (RCTs) to support treatment recommendations. The significance of an observed treatment-effect relies on the use of a boundary P-value, most commonly P<0.05. There is concern about relying on arbitrary threshold P-values to report results as ‘statistically significant’. The ‘fragility index’ (FI) has been proposed as an additional measure of the robustness of trial findings. FI is the minimum number of events needing to change from a non-event to an event in order to render a significant result non-significant. We calculated the FI to examine the robustness of statistically significant RCTs in CHF. Methods and results Two reviewers extracted data from RCTs supporting treatment recommendations in CHF guidelines. Twenty-five eligible trials were identified with a median sample size of 2331 patients (range 129–8399) and a median number of primary endpoints of 688.5 (range 88–2031). For the primary endpoint (analysed for 20 trials), the median FI was 26 (range 0–118). The FI was≤10 in 7 (35%) of these 20 trials, and in 4 (20%) trials the number of patients lost to follow-up in the treatment group exceeded the FI. Conclusion The results of some large RCTs in CHF hinge on a small number of events. The FI offers an additional, easy to understand metric, which augments the standard reporting of boundary P-values for statistical significance. The FI helps in the interpretation of the robustness of the results of RCTs. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results